Organisation paid for research Program year 2021 Source: CMS Open Payments

Inland Rheumlgy Clinical Trials Inc

Neither a doctor nor a teaching hospital

Research payments

$773,388

151 payments

Through program year 2021, Inland Rheumlgy Clinical Trials Inc is reported as receiving $773,388 in research payments, across 151 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$169,196	43
2020	Research	$339,561	56
2019	Research	$264,632	52

Breakdown

Who paid Research payments · program years 2019–2021

AbbVie, Inc. $773,388 151 payments

Studies the money was for Research payments · program years 2019–2021

M16-560 $162,276 10 payments
M15-554 $150,262 22 payments
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period $85,399 11 payments
M15-572 $78,331 20 payments
M16-063 $51,497 9 payments
M19-944 $44,097 6 payments
M13-549 $35,408 15 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) $22,487 2 payments
M19-130 $21,467 2 payments
M13-538 $19,429 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.